Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002971 | 0.93 | MAOA (0.40) | ALDH1A1CCR3MAOAMAOBPRKAB2 | |
| SCHEMBL1002428 | 0.91 | PARP1 (0.44) | ALDH1A1CCR3MAOAMAOBPRKAB2 | |
| SCHEMBL1002787 | 0.88 | CCR3 (0.41) | ALDH1A1CCR3MAOAMAOBPRKAB2 | |
| SCHEMBL1001844 | 0.88 | GRM2 (0.43) | ALDH1A1CCR3MAOAMAOBPRKAB2 | |
| SCHEMBL8240044 | 0.87 | ALDH1A1 (0.47) | ALDH1A1CCR3ACHEKDM4EGLA | |
| SCHEMBL8271945 | 0.87 | ALDH1A1 (0.46) | ALDH1A1ACHEKDM4EGLAGAA | |
| SCHEMBL2025301 | 0.84 | FPR2 (0.42) | ALDH1A1ATMMAPK1 | |
| SCHEMBL2019312 | 0.82 | KCNH2 (0.41) | ALDH1A1MAOBMAPK1 | |
| SCHEMBL12442996 | 0.81 | MAOA (0.37) | CCR3MAOAMAOBPRKAB2PRKAG1 | |
| SCHEMBL8240048 | 0.80 | PARP1 (0.41) | ALDH1A1CCR3ACHEKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | claimed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| CN-101309905-A | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2008-11-19 | — | — | CN | claimed |
| EP-1912940-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | claimed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | claimed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | ALDH1A1 1757/4885GRIN1 2/4885CCR3 2953/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | ALDH1A1 1582/4885GRIN1 2/4885CCR3 2513/4885 |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | ALDH1A1 1757/4885GRIN1 2/4885CCR3 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.